Zozulya S A, Tikhonov D V, Kaleda V G, Klyushnik T P
Mental Health Research Centre, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(6):59-66. doi: 10.17116/jnevro202112106159.
To study clinical, psychopathological and immunological features of remission after first-episode psychosis in young patients to determine the patterns of this stage and the possibility of using the results for monitoring, prognosis and optimization of therapy.
Fifty patients, aged 15-25 years, mean age 20.8±2.2 years, experiencing first-episode psychosis (F20, F25) and 45 healthy age-matched young men (mean age 19.2±3.2 years) were examined. The average age of psychosis manifestation was 19.8±2.5 months. Clinical, psychopathological, psychometric (PANSS and HDRS) and immunological («Neuro-immuno-test» technology) examinations were carried out at the psychotic state, during period of psychopathological symptoms reduction and further for 1-2 years until complete/significant reduction of psychotic symptoms.
Three stages of remission are revealed: I - the stage of reduction and modification of leading psychotic symptoms, II - the stage of stabilization of mental functions, III - the stage of reintegration of mental functions. It has been shown that each stage corresponds to different features of clinical symptoms and also certain spectra of immune markers (activity of leukocyte elastase, α1-proteinase inhibitor and level of autoantibodies to S100-B and OBM proteins) in blood serum of patients. The differences in the spectra of immune parameters at the second stage of remission in patients with affective (depressive) disorders define various patterns of post-psychotic development of disease. The most representative are immunological features of the third stage of remission.
The dynamics of immune markers in the course of remission can be considered as a biological criterion for assessment of the outcome of the first first-episode psychosis and the completeness of remission.
研究青年患者首次发作精神病缓解期的临床、精神病理学和免疫学特征,以确定该阶段的模式,以及将研究结果用于监测、预后评估和优化治疗的可能性。
对50例年龄在15至25岁之间、平均年龄为20.8±2.2岁、首次发作精神病(F20、F25)的患者以及45例年龄匹配的健康青年男性(平均年龄19.2±3.2岁)进行检查。精神病发作的平均年龄为19.8±2.5个月。在精神病状态、精神病理学症状减轻期间以及之后1至2年直至精神病症状完全/显著减轻期间,进行临床、精神病理学、心理测量(阳性和阴性症状量表及汉密尔顿抑郁量表)和免疫学(“神经免疫检测”技术)检查。
揭示了缓解的三个阶段:I - 主要精神病症状减轻和改变阶段,II - 心理功能稳定阶段,III - 心理功能重新整合阶段。结果表明,每个阶段对应不同的临床症状特征以及患者血清中某些免疫标志物谱(白细胞弹性蛋白酶活性、α1-蛋白酶抑制剂以及抗S100-B和OBM蛋白自身抗体水平)。情感(抑郁)障碍患者缓解第二阶段免疫参数谱的差异定义了精神病后疾病发展的不同模式。缓解第三阶段的免疫学特征最具代表性。
缓解过程中免疫标志物的动态变化可被视为评估首次发作精神病结局和缓解完整性的生物学标准。